Compare Ginkgo Bioworks Holdings Inc (DNA) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Omnicom Group Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Omnicom Group Inc. trades at $81.48 (market cap $23.01B). The key difference: Omnicom Group Inc. is far larger — about 39× Ginkgo Bioworks Holdings Inc's market cap, and Omnicom Group Inc. pays a 3.96% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | OMC | |
|---|---|---|
Market Cap | $590.53M | $23.01B |
Sector | Health | Media |
52-Week High | $16.14 | $85.80 |
52-Week Low | $5.48 | $67.27 |
Enterprise Value | $627.78M | $30.24B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Omnicom Group (OMC) trades at $82.55, up 0.76% today, with a bullish technical signal from moving averages. The stock shows mixed earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results due July 28, 2026. Revenue grew to $17.27B in 2025, though net income was negative, and cash flow improved significantly. Recent news highlights partnerships with IBM, Netflix, and NBCUniversal, enhancing its media and advertising solutions.
Outlook is cautiously optimistic with a consensus price target of $105.75, implying 28% upside, but risks include intense competition and thin profit margins. The stock offers value with a P/E of 12.16 and a dividend, yet investors should monitor earnings sustainability and debt levels amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
